Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2018 from OUS - Molecular characterization of mesenchymal cancer development

9 publications found

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
Patterns of genomic evolution in advanced melanoma
Nat Commun, 9 (1), 2665
DOI 10.1038/s41467-018-05063-1, PubMed 29991680

Fafilek B, Balek L, Bosakova MK, Varecha M, Nita A, Gregor T, Gudernova I, Krenova J, Ghosh S, Piskacek M, Jonatova L, Cernohorsky NH, Zieba JT, Kostas M, Haugsten EM, Wesche J, Erneux C, Trantirek L, Krakow D, Krejci P (2018)
The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases
Sci Signal, 11 (548)
DOI 10.1126/scisignal.aap8608, PubMed 30228226

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
Int J Mol Sci, 19 (4)
DOI 10.3390/ijms19040969, PubMed 29570692

Kostas M, Haugsten EM, Zhen Y, Sørensen V, Szybowska P, Fiorito E, Lorenz S, Jones N, de Souza GA, Wiedlocha A, Wesche J (2018)
Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors
Mol Cell Proteomics, 17 (5), 850-870
DOI 10.1074/mcp.RA117.000538, PubMed 29371290

Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
PLoS One, 13 (5), e0197456
DOI 10.1371/journal.pone.0197456, PubMed 29771965

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Mol Cancer Ther, 17 (11), 2473-2480
DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
Sample-Index Misassignment Impacts Tumour Exome Sequencing
Sci Rep, 8 (1), 5307
DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Zhen Y, Haugsten EM, Singh SK, Wesche J (2018)
Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4
Biochemistry, 57 (26), 3807-3816
DOI 10.1021/acs.biochem.8b00120, PubMed 29812912

 
Page visits: 180035